Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorSecond Affiliated Hospital of Wenzhou Medical University

About this trial

Anesthesia and perioperative Neurocognitive Disorders in the Elderly patients undergoing hip fracture Surgery platform trial (ANDES platform trial): A pragmatic multi-arm, adaptive, open label, multicenter randomized controlled platform trial to assess the effect of different enhance anesthesia technique in perioperative neurocognitive function, as compared to standard anesthesia care in the elderly patients undergoing hip fracture

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Aged 65 years and older.

Patients with unilateral hip fracture (including femoral neck, femoral head, intertrochanteric and subtrochanteric fractures) are scheduled for surgical treatment.

American Society of Anesthesiologists (ASA) physical status IV or below.

The patients or family members provide written informed consent.

Disqualifiers

Patients with multiple trauma or fractures (excluding trauma that the researcher judges will not affect the patient's overall recovery, such as simple spinal compression fractures, mild soft tissue contusions, fractures of hands and feet, etc.);

Two or more anesthetic surgeries are required.

Petients with an obvious history of head trauma (such as loss of consciousness for more than 5 minutes, post-traumatic amnesia, etc.);

Patients who the researcher believes are unable to complete the assessment of primary outcome;

Trial design

Design model

Parallel

Treatments tested in this trial

  • Nerve block+standard anesthesia

    Other intervention

    1. Receive nerve block as soon as possible after randomization; 2. Ultrasound-guided nerve block is recommended, with the iliacfascia block recommended as the blocking site; 3. It is recommended to use 1.33% bupivacaine liposome (long-acting), and the maximum dose should not exceed 133mg; or regular local anesthetic (bupivacaine or ropivacaine, etc.) with electronic analgesic pumping infusion; or multiple single injections of regular local anesthetics should be used to maintain the continuity of nerve block effect.

  • Intravenous lidocaine+standard anesthesia

    Drug

    1. Subjects randomly assigned to Lidocaine Group (Group L) will be given ECG monitoring, oxygen saturation monitoring, blood pressure monitoring and an open intravenous route on the morning of the surgery. It is recommended to start the infusion of Lidocaine as soon as possible in the ward. 2. It is recommended to use portable electronic infusion pump for drug delivery. The loading dose is 1mg/kg, and the maintenance dose range is 1\~2mg/kg/h. The specific dosage is determined by the anesthesiologist based on the patient's condition. The infusion ends when the patient leaves the Post-anesthesia care unit after surgery, and the infusion time and total amount should be recorded.

  • Bupivacaine liposome

    Drug

    1.33% bupivacaine liposome

  • Ultrasound-guided nerve block

    Device

    Ultrasound-guided nerve block

Treatment groups

1,860 Participants
are divided into 3 treatment groups
Group A: Nerve block + standard anesthesia protocolExperimental treatment 3 interventions
Group B: Intravenous infusion of lidocaine + standard anesthesia protocolExperimental treatment 1 intervention
Group C: Standard anesthesia protocolNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Incidence of Neurocognitive Disorders (NCD) events rate during the first 7 postoperative days

Neurocognitive Disorders includes: 1. Postoperative delirium (POD) was mesaured by 3D-CAM; 2. Neurocognitive decline was mesaured within 7 postoperative days by: Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA), and neuropsychological tests containing 5 cognitive latitudes (1. digit span test (DST); 2. trail making test (TMT); 3. Boston naming test (BNT); 4. auditory verbal learning test-Huashan version (AVLT-H);5. clock drawing test (CDT).), and active report of patients or family members).

Time frame
during the first 7 postoperative days

Secondary outcomes

1

Subtypes, severity, and duration of delirium

Using CAM-S, and in units of days from the onset of delirium symptoms to the disappearance of symptoms or when the patient is discharged.

Time frame
during the first 7 postoperative days
2

Neurocognitive decline in postoperative 7 days

Neurocognitive decline was mesaured by: Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA), or neuropsychological tests containing 5 cognitive latitudes (1. digit span test (DST); 2. trail making test (TMT); 3. Boston naming test (BNT); 4. auditory verbal learning test-Huashan version (AVLT-H);5. clock drawing test (CDT).), or active report of patients or family members.

Time frame
during the first 7 postoperative days
3

Delayed neurocognitive recovery during 30 postoperative days

This was mesaured by: Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA), or neuropsychological tests containing 5 cognitive latitudes (1. digit span test (DST); 2. trail making test (TMT); 3. Boston naming test (BNT); 4. auditory verbal learning test-Huashan version (AVLT-H);5. clock drawing test (CDT).), or active report of patients or family members.

Time frame
during 30 postoperative days
4

Hospital Anxiety and Depression Scale (HADs)

Time frame
during postoperative one year

Other outcomes

1

Incidence of adverse events

We will collect the following known potential risks of general and local anesthesia from the start of the intervention to the subject's discharge and assess the overall incidence: 1. cardiopulmonary resuscitation; 2. Malignant hyperthermia or anaphylaxis; 3. Aspiration pneumonia ; 4. Epidural hematoma ; 6\) Patients who did not need mechanical ventilation before surgery continued with unplanned mechanical ventilation for more than 6 hours after surgery; 7) Other adverse events during postoperative hospitalization.

Time frame
during hospitalization, an average of 7 days; through entire trial, an average of 1 year.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Second Affiliated Hospital of Wenzhou Medical University

Lead sponsor

Zhejiang Provincial People's Hospital

Collaborator

First Affiliated Hospital of Wenzhou Medical University

Collaborator

Ningbo No.2 Hospital

Collaborator

Ningbo No.6 Hospital

Collaborator

Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

Collaborator

Taizhou Hospital

Collaborator

Affiliated Wenling Hospital of Wenzhou Medical University

Collaborator

Lishui Country People's Hospital

Collaborator

The Fifth Hospital Affiliated to Wenzhou Medical University/ Lishui Central Hospital

Collaborator

Jinhua Municipal Central Hospital

Collaborator

Dongyang People's Hospital

Collaborator

People's Hospital of Quzhou

Collaborator